Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies-Reference-Cited by-同舟云学术

Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies

Published:2024-01-11 Issue:3 Volume:44 Page:210-221
ISSN:2234-3806
Container-title:Annals of Laboratory Medicine
language:en
Short-container-title:Ann Lab Med

Author:

Kim Seok Jin¹²³^ORCID,Yoon Sang Eun¹³^ORCID,Kim Won Seog¹²³^ORCID

Affiliation:

1. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

2. Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University School of Medicine, Seoul, Korea

3. CAR T-cell Therapy Center, Samsung Comprehensive Cancer Center, Seoul, Korea

Funder

Korea Health Industry Development Institute

Ministry of Health and Welfare

National Research Foundation of Korea

Publisher

Annals of Laboratory Medicine

Link

https://pdf.medrang.co.kr/ALM/2024/044/alm-44-3-210.pdf

Reference87 articles.

1. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy

2. Engineering CAR-T cells

3. Driving CAR T-cells forward

4. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

5. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The method for assessing the specificity of developing CAR therapies;Biophysical Reports;2024-09

2. Lessons learned from the Eµ-TCL1 mouse model of CLL;Seminars in Hematology;2024-06

3. Effectiveness of CAR-T treatment toward the potential risk of second malignancies;Frontiers in Immunology;2024-05-02

4. Effectiveness of axicabtagene ciloleucel versus conventional treatments as first-line therapy for high-risk large B-cell lymphoma: an external comparator study;2024-03-25